Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for breast aesthetic and reconstructive plastic surgeries in Europe, the Middle East, Africa, Latin America, Asia, and the United States. The company offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides breast tissue expanders. The company sells products to physicians, hospitals, and clinics through distributors and its direct sales force. Establishment Labs Holdings Inc. was incorporated in 2004 and is based in Austin, Texas.…
Establishment Labs Stock Gets A Lift From Raised Revenue Outlook
Establishment Labs Holdings (NASDAQ: ESTA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 1,004 employees.
The shares were at 69.14 USD on 20 November 2026, up 9.4% over 52 weeks. Its 52-week range is 53.16 USD to 97.59 USD: the price is 29.2% below the high and 30.1% above the low.
Its market capitalisation is 2.06B USD.
Establishment Labs Holdings reports return on equity of -216.9%, an operating margin of -6.6% and revenue up 33.9% year over year.
Its debt exceeds its cash by 193.72M USD, a debt-to-equity ratio of 11.23. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Strong Buy; their mean price target of 98.00 USD is 41.7% above the current price. The next earnings report is expected on 23 February 2027.